STARTUP LEGAL6 Sept 2026
RPG Life Sciences bets on China-plus 1, goes on an API buying spree | Company Business News
RPG Life Sciences has spent ₹215 crore in five weeks to buy two makers of active pharmaceutical ingredients, or APIs. The Harsh Goenka group firm is betting the world wants less dependence on China and will buy from India. It has set aside ₹700 crore more. This could reshape ingredient supply for pharma firms. Small API makers may become takeover targets.
Key Statutory Highlights
- RPG Life Sciences spent ₹215 crore acquiring two API makers—Actis Generics for ₹80 crore and Raghava Life Sciences' API business for up to ₹135 crore—in just five weeks.
- The company has committed up to ₹700 crore, together with private equity partner InvAscent, mainly for further acquisitions.
- The two deals nearly quintuple API capacity from about 110 kilolitres to roughly 505 kilolitres, and the Indian API market is estimated at upwards of ₹1 trillion.
Actionable Advice for Taxpayers / Founders:If you run or supply an API or pharma business, assess your customer concentration and product niches now—you could be an acquisition target, so keep your compliance records and contracts ready.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: